AbbVie Reports Positive Phase 3 Results for RINVOQ® in Vitiligo
NORTH CHICAGO, Ill., October 29, 2025 — AbbVie Inc. (NYSE: ABBV) announced positive topline results from two replicate Phase...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
NORTH CHICAGO, Ill., October 29, 2025 — AbbVie Inc. (NYSE: ABBV) announced positive topline results from two replicate Phase...
INDIANAPOLIS, Ind., October 24, 2025 — In a landmark decision for veterinary medicine and regulatory preparedness, Elanco Animal Health...
RAHWAY, N.J., September 26, 2025 – Merck Animal Health, known as MSD Animal Health outside the U.S. and Canada...
